Prepare your organization for the next era of global pricing and market access.
The US Most Favored Nation (MFN) pricing framework is rewriting how companies approach pricing architecture and launch sequencing across every market touched by its reference baskets. At the same time, the EU Joint Clinical Assessment (JCA) is raising the evidence bar across 27 member states, with orphan medicines next in line by 2028. Together, they are not just changing what companies do. They are changing what is possible.
Watch a panel discussion featuring global industry leaders, market access experts, and former policymakers as they examine how these policy shifts are affecting both established and emerging pharmaceutical companies. Drawing on insights from Certara’s original 2026 survey of market access professionals, the panel exploresthe strategic implications of MFN and JCA, discusses where organizations are adapting their strategies, and examines what these changes mean for both mature and emerging markets.
Whether you’re preparing for future launches, developing global pricing strategies, or anticipating evolving evidence expectations, this webinar provides a timely perspectives to help inform your decision-making.
You’ll gain insights into:
- How the U.S. MFN pricing framework is influencing global pricing and launch sequencing strategies
- The evolving impact of the EU HTA reform on access strategy and evidence expectations across Europe.
- How companies are balancing pricing, reimbursement, and access strategy across diverse global markets
- The implications of these policy changes for both large HTA-mature markets and smaller, resource-constrained healthcare systems
Who should watch
Leaders and professionals across global market access, pricing & reimbursement, regulatory, commercial and launch strategy, and HEOR and evidence generation teams looking to understand what’s changing and how to prepare.
Why watch
The intersection of MFN pricing policy and EU HTA reform represents one of the most significant shifts in global pharmaceutical market access in recent years. Hear directly from industry experts and policymakers as they discuss emerging trends, share diverse perspectives, and offer practical insights into preparing for what’s next.
演讲嘉宾：
- Roman Casciano, RPh, MS
Senior Vice President, Certara – Session Moderator - Prof. Dr. med. Jörg Ruof, MBA, MPH
r-connect; Founder, European Access Academy (EAA) - Michał Worotyński
Group Market Access Manager | Ewopharma Group - Krzysztof Łanda, M.D.
Founder of Watch Health Care Foundation - Adam Parnaby
Lead, Global Policy & Access | Bristol Myers Squibb
